Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer. First report

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T. Uwagawa
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors T. Uwagawa1, T. Sakamoto1, Y. Nakaseko1, Y. Takano1, K. Furukawa1, M. Kanehira1, S. Onda1, T. Gocho1, H. Shiba1, Y. Arakawa1, K. Aiba2, K. Yanaga3
  • 1Jikei University School of Medicine, Minato-ku, Japan, /
  • 2Division of Clinical Oncology/Hematology, The Jikei University School of Medicine, Minato-ku, Japan, /
  • 3The Jikei University School of Medicine, Japan, Minato-ku, Japan, /

Abstract

Chemotherapeutic agent-induced nuclear factor kappa b (NF-?B) activation has been reported as a key mechanism of chemoresistance. We previously reported that nafamostat mesilate (NAM), a synthetic serine protease inhibitor, inhibits NF-?B activation by inhibiting phosphorylation of I?Bα. Based on these facts, phase II study of gemcitabine (GEM) with regional arterial infusion of NAM for advanced pancreatic cancer was conducted as a translational research. Overall survival of NAM/GEM was 10.0 months. Subsequently, a novel phase II study of combination chemotherapy of NAM/GEM with S-1, an oral fluoropyrimidine was planned (UMIN 000008413).